Study: Merck and Daiichis Lung Cancer Treatment Shows Promise
MRK and Daiichi Sankyos patritumab deruxtecan shows statistically significant progression-free survival improvement in previously treated EGFR-mutated NSCLC.…
88,800$
-0,79%
Echtzeit-Aktienkurs Merck & Co. Inc.
Bid:
Ask:
Nachrichten zur Merck & Co. Inc. Aktie
09:44: Merck: Inline-Optionsscheine mit hohen Seitwärtschancen
Die
Merck-Aktie (ISIN: DE0006599905) prallte in den vergangenen Monaten bereits zwei
mal von ihrem Jahreshoch im Bereich von 177 Euro nach unten…
DAX startet leicht verbessert – Aixtron, Ionos, Merck, Sartorius, Siemens, SÜSS und Zalando im Check
Zum Wochenstart hat sich der deutsche Aktienmarkt eine kleine Verschnaufpause gegönnt und 0,35 Prozent an Wert abgeben müssen. Der Dienstag…
NuCana Stock Soars 151% on Upbeat Efficacy Data From Melanoma Study
NCNA stock surges 151% on positive efficacy data from the mid-stage melanoma study of NUC-7738 in combination with Mercks Keytruda.…
Newsblog zum Unternehmen: Siemens baut Partnerschaft mit Merck aus
Siemens und der Pharmakonzern intensivieren ihre Zusammenarbeit im Bereich der modularen Produktion. +++ Alles Entwicklungen zu Siemens im Newsblog. +++…
Merck’s Top-Seller Cements Status in Hard-to-Treat Breast Cancer
Merck & Co.’s best-selling drug Keytruda helped women with a hard-to-treat form of breast cancer live longer, according to the…
Merck Appears Ready To Return To June Highs (Technical Analysis)
…
Moderna cites 2025 launch for Merck partnered cancer vaccine: report
…
Top Biotech, With 85% Gain This Week, Rockets Again On Sale
The company is adding onto its success outperforming Mercks top drug in lung cancer patients.…
Merck: Es läuft wie geschmiert - Explosionsartige Umsatzzuwächse aber nicht erwartet - Aktienanalyse
Wien (www.aktiencheck.de) - Merck-Aktienanalyse von der Raiffeisen Bank International AG:
Raphael Schicho, Analyst der Raiffeisen Bank International AG (RBI), erhöht das…
Merck Aktie: Innovatives ADC-Reaktor stärkt Marktposition
Merck, ein führendes Wissenschafts- und Technologieunternehmen, hat den ersten skalierbaren Einweg-Mischer speziell für die Herstellung von Antikörper-Wirkstoff-Konjugaten (ADCs) auf den…
Summit Hits Record High on Lung Cancer Drug Topping Mercks Keytruda
Data from a late-stage study shows that SMMTs experimental antibody beat Keytruda in a head-to-head setting in treating certain patients…
MRK Stock Dips After SMMTs Cancer Drug Outshines Keytruda in Study
Mercks Keytruda is the standard of care for NSCLC. Ivonescimab, however, shows clinically meaningful benefit over Keytruda in a phase…
Apples iPhone 16 launch, Mattel CEO: Market Domination
Its that time of day again, the final trading hour of Monday, September 9. Market Domination hosts Julie Hyman and…
Why Summit Therapeutics Rocketed Over 60% Today
The companys new lung cancer treatment could unseat Mercks Keytruda in the $50 billion-plus lung cancer treatment market.…
Why Summit Therapeutics Rocketed Over 60% Today @themotleyfool #stocks $SMMT $MRK
The companys new lung cancer treatment could unseat Mercks Keytruda in the $50 billion-plus lung cancer treatment market.…
Top Stock Movers Now: Boeing, Palantir Technologies, Merck, Alphabet, and More
U.S. equities rallied back from last weeks selloff at midday as investors put more money into blue chip stocks.…
Stocks making the biggest premarket moves: Boeing, Dell, Merck and more
These are the stocks posting the largest moves in the premarket.…
Merck, Daiichi post mid-stage data for novel lung cancer drug
…
Merck & Co., Inc. (MRK) CEO Rob Davis presents at Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)
…
Kurs der Merck KGaA-Aktie verharrt auf Vortags-Niveau (170,25 €)
Am deutschen Aktienmarkt ist die Aktie von Merck gegenwärtig unauffällig. Der jüngste Kurs betrug 170,25 Euro. Die Wertschätzung der Börsenteilnehmer…
Global Hematologic Malignancies Market Size To Worth USD 144.58 Billion By 2033 | CAGR Of 7.97%
The Global Hematologic Malignancies Market Size was Valued at USD 67.18 Billion in 2023 and the Worldwide Hematologic Malignancies Market…
Pharma Stock Roundup: EU Nod for Expanded Use of MRKs Keytruda & More
European Commission approves expanded use of Mercks Keytruda in bladder cancer. Sanofi & Lilly announce data from phase III studies…
Merck (MRK) Stock Moves -0.63%: What You Should Know
Merck (MRK) closed the most recent trading day at $117.84, moving -0.63% from the previous trading session.…
Whats Wrong With Mercks Stock?
Is the healthcare stock an underrated buy right now?…
Whats Wrong With Mercks Stock? @themotleyfool #stocks $MRK
Is the healthcare stock an underrated buy right now?…
Vaxcyte Stock Hits Record High on Pneumococcal Vaccine Study Results
Data from an early-stage study shows that PCVXs pneumococcal vaccine has achieved immune responses rivaling vaccines marketed by Pfizer and…
Mercks Keytruda & Padcev Combo Gets EU Nod for Urothelial Carcinoma
MRKs Keytruda gets approval in combination with Astellas and Pfizers Padcev for treating first-line advanced urothelial carcinoma.…
Updating Walmart, Merck And Nike Post-Earnings
…
BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin
FLORHAM PARK, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a…
Mercks Change To Profit Guidance Provides An Opportunity
…
Best-performing Small-cap Biotech Stocks on the ASX in 2024
The global biotechnology sector is on track to become a multi-trillion dollar industry. Worldwide, the biotech space is worth an…
Merck scraps two late-stage trials of cancer drug Keytruda
Merck has stopped two separate late-stage studies of its immunotherapy Keytruda in patients with skin and lung cancers, the company…
MRK Begins 2nd Phase III Study on Rare Blood Disorder Candidate
Merck begins the second phase III study on its LSD1 inhibitor, bomedemstat, for treating certain patients with essential thrombocythemia, a…
Merck Stock Worth Watching on PAH Drug Winrevairs Approval in Europe?
MRKs Winrevair becomes the first novel activin signaling inhibitor therapy approved in Europe to treat PAH.…
Merck, Bristol Myers cancer drugs included in September FDA advisory panel meeting
…
Merck (MRK) Falls 10% in 3 Months: Should You Buy the Dip?
Declining estimates and the recent price drop make investors skeptical about holding Mercks (MRK) stock.…
Top Analyst Reports for Costco, Merck & Linde
Todays Research Daily features new research reports on 16 major stocks, including Costco Wholesale Corporation (COST), Merck & Co., Inc.…
Merck Aktie: Kurssteigerung und Prognosen
Aktuelle Kursentwicklung Am heutigen Handelstag legte die Merck-Aktie im XETRA-Handel ab 15:53 Uhr um 0,6 Prozent zu und notierte bei…
Merck & Co: Eine Reihe von Herausforderungen und Chancen - Aktienanalyse
Wien (www.aktiencheck.de) - Merck & Co-Aktienanalyse von der Raiffeisen Bank International AG:
Raphael Schicho, Analyst der Raiffeisen Bank International AG (RBI),…
Kurs der Merck, inc-Aktie verharrt auf Vortags-Niveau (102,7406 €)
Der Kurs der dem Anteilsschein von Merck, inc kommt kaum von der Stelle. Zuletzt zahlten Investoren für das Papier 113,14…
Pharma Stock Roundup: AZN Gets Approvals for Imfinzi Expanded Use, MRK Inks New Deal
Merck (MRK) signs a new collaboration with a private drugmaker. AstraZeneca (AZN) gets approvals for expanded use of Imfinzi.…
Mercks Weakness Could Mean Profits With This Bearish Option Trade
Merck stock is down 11% in the last three months and could potentially be headed for new lows.…
Merck: Buy This Bargain Before Its Gone
…
Merck: 205 oder 180 Euro? Alle Kursziele und Ratings nach Q2-Zahlen auf einen Blick - Aktiennews
Darmstadt (www.aktiencheck.de) - Welche Kursziele und Ratings trauen die Analysten der führenden Banken und Research-Häuser der Merck-Aktie (ISIN: DE0006599905, WKN:…
Merck (MRK) to Buy Curons Bispecific Antibody Drug for $1.3B
Merck (MRK) to acquire worldwide rights to a novel investigational clinical-stage bispecific antibody for treating B-cell-associated diseases. The deal is…
Investing in Merck (NYSE:MRK) three years ago would have delivered you a 63% gain
While Merck & Co., Inc. ( NYSE:MRK ) shareholders are probably generally happy, the stock hasnt had particularly good...…
Aktie von Merck, inc: Kurs nur geringfügig im Minus (103,7226 €)
CODE Das Wertpapier notiert derzeit bei 113,29 US-Dollar. Die Wertschätzung der privaten und institutionellen Anlegern für die Aktie von Merck,…
JPMorgan belässt Merck KGaA auf Overweight - Ziel 190 Euro
NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Merck KGaA nach Zahlen für das zweite Quartal…
Pharma Stock Roundup: LLY, NVO, BAYRY Q2 Earnings, MRKs New Deal & Other Updates
Eli Lilly (LLY), Novo Nordisk (NVO) and Bayer (BAYRY) announce second-quarter results. Merck (MRK) expands existing co-development deal with partner…